Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant/educational grants from Daiichi Sankyo, Inc.; Foundation Medicine, Inc.; and Jazz Pharmaceuticals.

Pathology Perspectives: Establishing the Role of Predictive Markers and Testing Strategies in AML Management

Release Date: April 30, 2019
Expiration Date: April 30, 2020
Media: Internet - based

Activity Overview

This online activity includes expert perspectives on the ever-advancing role of molecular techniques in diagnosing and managing acute myeloid leukemia (AML). This activity will address multiple topics in one of the key components of the multidisciplinary management of AML: optimizing pathology testing and incorporating that information to guide therapeutic choices. Topics include the full spectrum of AML management from the perspectives of pathologists and oncologists, from prognostic indicators and the role of molecular pathology in diagnosis to the use of molecular testing during and following each stage of treatment. What to test for and which techniques are appropriate at different testing stages also will be discussed. This review of current and emerging data will help you integrate the latest advances in the diagnosis and management of AML into clinical context for the care of your patients.

CME Activity Table of Contents

  • Pretest
  • Module 1: Advances in AML Diagnosis and Treatment Through the Years
  • Module 2: An Update on Evolving Strategies for Identification of Molecular Markers in Acute Leukemias: Focus on AML
  • Module 3: Synthesizing What We Know Now to Inform Appropriate Use of Current Therapies in AML
  • Posttest

Acknowledgement of Commercial Support

This activity is supported by an educational grant/educational grants from Daiichi Sankyo, Inc.; Foundation Medicine, Inc.; and Jazz Pharmaceuticals.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward pathologists and medical oncologists who treat patients with AML. Nurses, nurse practitioners, physician assistants, and other healthcare professions involved in the treatment and management of hematologic malignancies, specifically AML, will also be invited to participate in the activity.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Identify current best practices in the molecular, karyotypic, mutational analysis of AML in collaboration with pathology colleagues to inform treatment approaches
  • Outline current recommendations in AML as described by the American Society of Hematology/College of American Pathologists (ASH-CAP) guidelines
  • Evaluate multidisciplinary strategies to facilitate AML diagnosis and ensure all prognostic and predictive features of these tumors are incorporated into clinical decision making

Faculty, Staff, and Planners’ Disclosures

Daniel A. Arber
Daniel A. Arber, MD
Donald West and Mary Elizabeth King Professor
Chair, Department of Pathology
University of Chicago
Chicago, IL

Disclosures: Consultant: Jazz Pharmaceuticals.

Joseph D. Khoury
Joseph D. Khoury, MD, FCAP, CMQ
Professor, Department of Hematopathology
Executive Director
Division of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Speaker/Educational Program: Aptitude Health and Medicom.

Eytan M. Stein
Eytan M. Stein, MD
Assistant Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Research Support: Bayer, Celgene, Agios, Syros; Consultant: Astellas, Celgene, Agios, PTC Therapeutics, Daiichi Sankyo, Genentech; Shareholder: Auron Therapeutics

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By